[TGF-beta/Smad in prostate cancer: an update]
- PMID: 19947572
[TGF-beta/Smad in prostate cancer: an update]
Abstract
Tumorigenesis and cancer progression are closely associated with the transforming growth factor-beta (TGF-beta) and its downstream component Smad. The TGF-beta/Smad signaling pathway, which is activated in prostate cancer, has a regulatory effect on cell adhesion, the actin filament system and cell cycle, as well as the expression of specific genes. Meanwhile, other protein signals such as MAPK and PI3K/Akt/mTOR and some genes may act on the expression of the TGF-beta/Smad pathway. This article updates recent researches on the expression, action and regulatory effect of the TGF-beta/Smad signaling pathway in prostate cancer.
Similar articles
-
ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells.Oncogene. 2006 Sep 14;25(41):5591-600. doi: 10.1038/sj.onc.1209571. Epub 2006 Apr 24. Oncogene. 2006. PMID: 16636667
-
An imbalance between Smad and MAPK pathways is responsible for TGF-beta tumor promoting effects in high-grade gliomas.Int J Oncol. 2007 Feb;30(2):499-507. Int J Oncol. 2007. PMID: 17203233
-
Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.Eur Urol. 2005 Dec;48(6):1051-8. doi: 10.1016/j.eururo.2005.09.006. Epub 2005 Oct 14. Eur Urol. 2005. PMID: 16257107
-
Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis.Oncogene. 2005 Aug 29;24(37):5742-50. doi: 10.1038/sj.onc.1208928. Oncogene. 2005. PMID: 16123807 Review.
-
Dynamic control of TGF-beta signaling and its links to the cytoskeleton.FEBS Lett. 2008 Jun 18;582(14):2051-65. doi: 10.1016/j.febslet.2008.03.027. Epub 2008 Mar 28. FEBS Lett. 2008. PMID: 18375206 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous